Precision medicine as a predictive factor for risk of hospitalization of recurrent ischemic stroke patients treated with low dose aspirin. A pilot study

Figures & data

Table 1. The severity of prognosis after 12 weeks of aspirin administration.

		Number of patients (n)	Percentage %
Severity	Mild to moderate	42	77.8%
	severe	12	22.2%

Table 2. Routine laboratory investigations of studied patients.

	Recurrent
	YES		NO		P value
	Mean	Standard Deviation	Mean	Standard Deviation
HDL-c (mg/dl)	38.07	9.88	33.88	13.41	0.289
T. Chol. (mg/dl)	197.50	35.37	203.83	41.08	0.610
TG (mg/dl)	180.29	83.49	154.32	60.80	0.390
NIHSS	16.14	7.07	12.30	6.41	0.021*
LDL-c (mg/dl)	123.66	35.03	140.75	40.84	0.169
TNF-alpha (pg/ml)	63.57	20.68	54.58	30.40	0.418

*Statistically significant value (p-value<0.05); Data are presented as mean and standard deviation.

¹HDL-c, high-density lipoprotein; CH, cholesterol; TG, triglyceride; NIHSS: National Institutes of Health Stroke scaling; LDL-c, low-density lipoprotein; TNF-alpha, Tumor necrosis factor alpha.

Table 3. Association of prophylactic aspirin to Rs1057910 genotype and routine clinical investigations.

		Recurrent
		YES		NO		P value
		Number of patients (n)	Row N %	Number of patients (n)	Row N %
DM	YES	4	22.2%	14	77.8%	0.751
	NO	10	27.8%	26	72.2%
HTN	YES	12	34.3%	23	65.7%	0.102
	NO	2	10.5%	17	89.5%
Smoking	YES	6	31.6%	13	68.4%	0.528
	NO	8	22.9%	27	77.1%
Rs1057910	A/C	3	30.0%	7	70.0%	0.708
	AA	11	25.0%	33	75.0%

²DM, Diabetes Mellitus; HTN, Hypertension.

Table 4.: Multivariate logistic regression analysis with adjustment of the traditional risk factors hypertension, diabetes mellitus, low-density lipoprotein-c.

		P value	AAOR	95% C.I.
				Lower	Upper
Stoke recurrence	Age	0.947	1.002	0.932	1.078
	HDL-c (mg/dl)	0.700	1.012	0.953	1.074
	CH (mg/dl)	0.351	1.024	0.974	1.077
	TG (mg/dl)	0.804	1.002	0.989	1.014
	NIHSS	0.119	1.080	0.980	1.189
	LDL-c (mg/dl)	0.189	0.966	0.917	1.017
	TNF- α (pg/ml)	0.161	1.021	0.992	1.052
	DM	0.748	0.765	0.149	3.921
	Smoking	0.471	1.695	0.403	7.125
	Rs1057910 (A/C)	0.479	1.901	0.321	11.257

³HDL-c, high-density lipoprotein; CH, cholesterol; TG, triglyceride; NIHSS: National Institutes of Health Stroke scaling; LDL-c, low-density lipoprotein; TNF-alpha, Tumor necrosis factor alpha. DM, Diabetes mellitus.

Table 5. Association of Rs1057910 genotypes to stroke prognosis and inflammatory mediator (TNF- α).

	rs1057910
	A/C		AA		P value
	Mean	Standard Deviation	Mean	Standard Deviation
NIHSS	12.30	5.81	13.52	6.97	0.695
TNF-alpha	62.40	28.52	55.66	28.42	0.593

⁴NIHSS: National Institutes of Health Stroke scaling; TNF-alpha, Tumor necrosis factor alpha.

Table 6. The frequency of Rs1057910 alleles in relation to stroke recurrence, artery subtypes and severity of prognosis.

		Rs1057910 alleles
		allele C		allele A		P value
		Number of patients (n)	Column N %	Number of patients (n)	Column N %
Recurrent	YES	3	30.0%	25	25.5%	0.717
	NO	7	70.0%	73	74.5%
artery groups	SAA	5	50.0%	37	39.4%	0.520
	LAA	5	50.0%	57	60.6%
severity	mild to moderate	9	90.0%	75	76.5%	0.453
	severe	1	10.0%	23	23.5%

⁵SAA, small atherosclerotic artery; LAA, large atherosclerotic artery.

Table 7. Correlation between stroke prognosis and tumor necrosis factor- α.

		TNF- α
NIHSS	Correlation Coefficient	0.277
	P value	0.043*
	N	54

⁶NIHSS: National Institutes of Health Stroke scaling; TNF-α, Tumor necrosis factor alpha

Table 8. Area under the ROC Curve for TNF-alpha in ischemic stroke.

	Area Under the ROC Curve	P value	95% Confidence Interval
			Lower Bound	Upper Bound
TNF- α^7	0.555	0.594	0.354	0.755

⁷TNF- α, Tumor necrosis factor alpha

Figure 1. Bar chart representing the effect of the prognosis on ischemic stroke recurrence and non-recurrence.

Figure 2. Receiver operating characteristic curve for TNF-alpha in ischemic stroke.